BSX » Topics » increases

This excerpt taken from the BSX 8-K filed Jan 17, 2006.
increases when the market believes Boston Scientific will prevail in its bid for Guidant demonstrates this potential upside and must be taken into account when reviewing our proposal relative to any counter-proposal from Johnson & Johnson (“J&J”). To ensure that there is clarity among your Board and shareholders about these merits, the balance of this letter outlines why we believe that partnering with Boston Scientific represents the most sustainable, value-enhancing opportunity for Guidant, its shareholders and its employees.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki